89 Bio, Inc., was incorporated in June 2019 as a Delaware corporation to conduct the business of 89 Bio, Ltd., which was incorporated in Israel in January 2018. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases. The company's lead product candidate, pegozafermin, is a specially designed glycoglycolated analog of fibroblast growth factor that is currently being developed for the treatment of non-alcoholic steatohepatitis and for the treatment of severe hypertriglyceridemia. 

ETNB(Delisted)